In total, 4580 Staphylococcus aureus, 6125 Streptococcus uberis, 2264 Streptococcus dysgalactiae, 3287 Escherichia coli and 1066 coagulase-negative staphylococci were analyzed, showing 96.7%, 94.7%, 99.2%, 88.5% and 98.1% susceptible strains, respectively. (Photo S. Piepers)

Boehringer Ingelheim at the National Mastitis Council Regional Meeting in Ghent

Boehringer Ingelheim is very proud to be one of the major sponsors of the first National Mastitis Council (NMC) meeting to be held in Europe, where it will present two posters on Ubrolexin®.

Read more